Risk-based Monitoring (RBM) is quickly becoming the standard model for clinical development trial execution. Quintiles, as the RBM market leader, is delivering benefits from their RBM approach to improve data and study quality, enable faster, more informed decisions, and enhance patient safety, while mitigating risk.
Register for this webinar to understand how to:
Dr. Jonas Renstroem
Associate Director, Strategic Solutions
Jonas Renström holds both a M.Sc and a M.Ed from Uppsala University, Uppsala, Sweden, in addition to a Ph.D in experimental hematology from TUM, Munich, Germany.
Joined Quintiles in 2009 as part on the in-house monitoring team.
Since then Jonas has held several leadership positions within the Quintiles clinical operations organization and is now part of the Quintiles Risk Based Monitoring leadership team, mainly focusing on change management and operational innovation.
Senior Director, Global Project Leadership
Edward Tumaian holds a B.Sc. in Biology from Villanova University. Prior to joining Quintiles, he spent over 20 years working in life-sciences and healthcare, building and leading teams in portfolio management, clinical operations, and partnership management in the Biopharmaceutical industry. Created new partnerships by encouraging and translating strategic vision into successful delivery. Focused alignment on shared goals and objectives which resulted in numerous regulatory approvals for both products and devices to solve patients' unmet needs.
Ed has held several leadership positions with 3 years in the Quintiles Customer Solutions Management Group organization, and is now on the Quintiles’ leadership team for Risk Based Monitoring, leveraging his Customer Champion and Project Leadership experience in supporting the deployment and customer support of the RBM model.